Hikal's active pharmaceutical ingredient facility in Bengaluru has received a Certificate of GMP Compliance of a Manufacturer from Swissmedic, Switzerland's therapeutic-products regulator. The company announced the certification in an exchange filing dated 30 October 2026.
The certificate confirms that the facility meets Good Manufacturing Practice requirements under the Mutual Recognition Agreement between the European Union and Switzerland. Hikal said the approval strengthens the site's regulatory position and expands its ability to serve customers in Europe and other regulated markets.
Certification follows other regulator inspections
The Bengaluru facility has also completed inspections by Brazil's health regulator ANVISA and Japan's Pharmaceuticals and Medical Devices Agency. Hikal said the three recognitions support its plan to diversify the geographic reach of its pharmaceutical business.
Regulatory certification is a condition for serving many pharmaceutical customers, but it is not the same as a customer order or a revenue commitment. Commercial conversion will depend on product registrations, customer qualification, contracts, production scheduling and continuing compliance with the applicable standards.
The site manufactures active ingredients
Hikal supplies active ingredients, intermediates and biocides to pharmaceutical, animal-health, biotechnology, personal-care and specialty-chemical customers. Its Bengaluru site forms part of a five-facility Indian manufacturing network that also includes Taloja and Mahad in Maharashtra and Panoli in Gujarat.
The company also operates a research and technology centre in Pune. The filing does not state which products will be supplied under the new certification, the capacity available at the Bengaluru plant or the expected revenue contribution from customers in newly accessible markets.
Continued compliance remains central
GMP certification reflects the facility and systems reviewed by the regulator. Maintaining the commercial benefit requires ongoing adherence to quality, documentation, validation and change-control requirements. Customers may also conduct their own audits before approving a site for a product.
The disclosure does not provide the certificate's validity period, any product-specific limitations or planned capital expenditure following the approval. Those details are relevant to assessing how quickly the certification can translate into additional manufacturing volumes.
Key numbers
- Filing date: 30 October 2026
- Indian manufacturing facilities: five
- Bengaluru facility focus: active pharmaceutical ingredients
- Other named regulators: two, ANVISA and PMDA
- Research and technology centres named: one, in Pune
What boards and CFOs should note
- Which customer qualifications and product registrations are still required after the Swissmedic certification?
- What validated capacity at Bengaluru is available for regulated-market contracts?
- Which continuing compliance costs and audit obligations accompany access to the new markets?
Source: Hikal NSE filing, 30 October 2026. This is a summary of an official company filing, published as general information. It is not legal, tax or investment advice.
This article is journalism and commentary. It is not a recommendation to buy or sell any security, and it is not professional advice. Read the full disclaimer.
